Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  6.50 21.31% 37.00 3,667,706 16:45:49
Bid Price Offer Price High Price Low Price Open Price
37.00 38.00 37.50 30.50 30.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.62 -1.17 58
Last Trade Time Trade Type Trade Size Trade Price Currency
16:45:49 O 80,363 37.50 GBX

Skinbiotherapeutics (SBTX) Latest News (2)

More Skinbiotherapeutics News
Skinbiotherapeutics Investors    Skinbiotherapeutics Takeover Rumours

Skinbiotherapeutics (SBTX) Discussions and Chat

Skinbiotherapeutics (SBTX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 18:18:1037.5080,36330,136.13O
2021-01-22 17:58:4737.50110,76141,535.38O
2021-01-22 17:58:1737.00110,76140,981.57O
2021-01-22 17:28:4737.2234,50312,842.02O
2021-01-22 16:59:3337.5061,08322,906.13O
View all Skinbiotherapeutics trades in real-time

Skinbiotherapeutics (SBTX) Top Chat Posts

Skinbiotherapeutics Daily Update: Skinbiotherapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 30.50p.
Skinbiotherapeutics Plc has a 4 week average price of 15.50p and a 12 week average price of 7.58p.
The 1 year high share price is 37.50p while the 1 year low share price is currently 5.75p.
There are currently 155,889,922 shares in issue and the average daily traded volume is 1,391,532 shares. The market capitalisation of Skinbiotherapeutics Plc is £57,679,271.14.
christopher logsdon: Just looked at the share price. Well I didn't expect that!
aquaesulis01: zedder, I suspect the answer is a combination of the two. Despite being overweight here, I have bought each time the price to buy has dropped below 30p as I am now stocking up for my son and daughter as I fully expect this to be 10x this share price in two years time. If it just Seneca Partners Limited selling down and no ii replacing them, then happy with that as it will hopefully give me the time I need from other investments to open separate stocks and shares ISA's for them and to transfer in the funds purchase direct at today's levels. So in summary, I don't care in the short term whether the slack is being taken up by another ii or pis with less sticky fingers
judijudi: At the bottom of our website there is a running bar with ours, Croda’s, Optibiotix, the ftse and Integumens share prices? Why Integumen?
1marcr: I'm guilty of selling some of my holdings 27k at 36.01 and 20k at 31. My ride is now a free one. Plus if the share price drops much I'll buy back in.
rafboy: I think the Croda deal will prove a real success given time. As for end of year share price I will say it will be at least double the current share price in my view.
nik7907: Have sent email. Whilst I was looking for email I noticed on the sbtx site that the share price of sbtx, opti ,croda and skin(now dvrg) were scrolling along the bottom. Have Sbtx got anything going on with integumen/deepverge that I have missed?
owenmo: Putting a note in my diary; 29/9/2020 share price SBTX AND OPEN ORPHEN- 18.5p apiece! cutting edge stuff. Which way their respective share prices into 2021? Time will tell.
aquaesulis01: mad; it would be helpful if the Company explained the logic for setting the value of the options. I suspect the option price is set based on the share price on the award date; hence on April 18th 2018 the share price was 17.5p and hence the options awarded to Stuart were set at 18p, whilst on the date of the options awarded to Stuart in 2020 (17th April), the share price had collapsed because of the Covid situation, to 8.5p. It is unfortunate and inexplicable that the company failed to announce the award at the time, because announcing it at a time when the share price had recovered to 19p sent out a very negative message.
madaboutmed: There are usually various options. The recent grant to the CSO and CEO appear to be triggered by new commercial agreements and / or a target share price that is normally considerably higher than it stands at the time of issue so they are incentivised to deliver commercial deals / revenue to achieve the triggers and thus drive the share price upwards. IMHO DYOR
jansky61: RAF I posted on the OPTI BB recently that I think sales of SBTX products will be more visible to the market until OPTI produce an RNS or announcement with some figures. I'm no chartist but over the last 12 months OPTI are down from 67p to 57p and SBTX are up from 17p to 26p. I believe this trend will continue at least in the short term and I'm unsure whether the recent rise in the OPTI share price is down to OPTI itself or the value of their stake in SBTX. 50/50 in each is the safe option! Good luck.
Skinbiotherapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 09:22:05